Journal List > J Korean Ophthalmol Soc > v.50(9) > 1008357

J Korean Ophthalmol Soc. 2009 Sep;50(9):1326-1333. Korean.
Published online September 23, 2009.  https://doi.org/10.3341/jkos.2009.50.9.1326
Copyright © 2009 The Korean Ophthalmological Society
Photodynamic Therapy With Verteporfin using Half Fluence for Chronic Central Serous Chorioretinopathy
Mun Hee Chang, MD, Seong Woo Kim, MD, PhD, Jae Ryung Oh, MD, PhD and Kuhl Huh, MD, PhD
Department of Ophthalmology, Korea University College of Medicine, Seoul, Korea.

Address reprint requests to Kuhl Huh, MD, PhD. Department of Ophthalmology, Guro Hospital, Korea University College of Medicine, #80 Guro-dong, Guro-gu, Seoul 152-703, Korea. Tel: 82-2-2626-1260, Fax: 82-2-857-8580, Email: dumky@unitel.co.kr
Received February 19, 2009; Accepted June 16, 2009.

Abstract

Purpose

To evaluate the clinical results of half-fluence photodynamic therapy (PDT) using verteporfin in patients with chronic central serous chorioretinopathy (CSC).

Methods

The author reviewed the charts of 20 patients (22 eyes) who underwent PDT for chronic central serous chorioretinopathy. All 22 eyes were treated using an irradiance of 300 mW over 83 second (25 J/cm2). Postoperative evaluation included improvements in visual acuity, complications, changes in central macular thickness with the optical coherence tomogram (OCT), and recurrence.

Results

The best-corrected visual acuity improved significantly from 0.50±0.32 to 0.12±0.19 logMAR at 3 months (p<0.01), and the mean central macular thickness decreased from 377.7±86.3 µm to 166.2±29.3 µm at 3 months (p<0.01). Exudative serous macular detachments were resolved completely in all eyes within 3 months. There was no recurrence after PDT during the follow-up period.

Conclusions

PDT using half fluence appeared to be a beneficial treatment option for patients with chronic CSC. Further studies are needed to verify treatment safety as well as the time and rate of recurrences.

Keywords: Chronic central serous chorioretinopathy; Half fluence photodynamic therapy

Figures


Figure 1
The left eye of a 38-year-old man (No. 8) (Table 1) with chronic central serous chorioretinopathy (CSC) showing a submacular neurosensory retinal detachment (A) and focal retinal pigment epithelium (RPE) leakage (B). (C) The baseline OCT showing a neurosensory retinal detachment in the macular region. (D) Red-free fundus photography taken 3 months after PDT showing no submacular neurosensory retinal detachment. (E) Late phase FA taken 3 months after PDT showing no angiogenic leakage. (F) The OCT image obtained at 3 months showing complete resolution of the subretinal fluid.
Click for larger image


Figure 2
The right eye of a 48-year-old man (No. 6) (Table 1) with chronic central serous chorioretinopathy (CSC) showing a submacular neurosensory retinal detachment (A) and focal retinal pigment epithelium (RPE) leakage (B). (C) The baseline OCT showing a neurosensory retinal detachment in the macular region. (D) Red-free fundus photograph taken 3 months after PDT showing no submacular neurosensory retinal detachment. (E) Late phase FA taken 3 months after PDT demonstrating the absence of fluorescein leakage at macula with window defect at the fovea. (F) The OCTimage obtained at 3 months showing complete resolution of the subretinal fluid.
Click for larger image

Tables


Table 1
The characteristics of patients
Click for larger image

References
1. Schatz H, Madeira D, Johnson RN, McDonald HR. Central serous chorioretinopathy occurring in patients 60 years of age and older. Ophthalmology 1992;99:63–67.
2. Gass JD. Pathogenesis of disciform detachment of the neuroepithelium: II Idiopathic central serous choriodopathy. Am J Ophthalmol 1967;63:587–615.
3. Gass JD. In: Stereoscopic atlas of macular diseases: diagnosis and treatment. 4th ed. St. Louis: Mosby; 1997. pp. 52-70.
4. Costa RA, Scapucin L, Moraes NS, et al. Indocyanine green-mediated photothrombosis as a new technique of treatment for persistent central serous chorioretinopathy. Curr Eye Res 2002;25:287–297.
5. Prunte C, Flammer J. Choroidal capillary and venous congestion in central serous chorioretinopathy. Am J Ophthalmol 1996;121:26–34.
6. Gilbert CM, Owens SL, Smith PD, Fine SL. Long-term follow up of central serous choriortinopathy. Br J Ophthalmol 1984;68:815–820.
7. Wang MS, Sander B, Larsen M. Retinal atrophy in idiopathic central serous chorioretinopathy. Am J Ophthalmol 2002;133:787–793.
8. Idia T, Yannuzzi LA, Spaide RF, et al. Cystoid macular degeneration in chronic central serous chorioretinopathy. Retina 2003;23:1–7.
9. Robertson DM. Argon laser photocoagulation treatment in central serous chorioretinopathy. Ophthalmology 1986;93:972–974.
10. Piccolino FC. Laser treatment of eccentric leaks in central serous chorioretinopathy resulting in disappearance of untreated juxtafoveal leaks. Retina 1992;12:96–102.
11. Battaglia Parodi M, Da Pozzo S, Ravalico G. Photodynamic therapy in chronic central serous chorioretinopathy. Retina 2003;23:235–237.
12. Cardillo Piccolino F, Eandi CM, Ventre L, et al. Photodynamic therapy for chronic central serous chorioretinopathy. Retina 2003;23:752–763.
13. Chan WM, Lam DS, Lai TY, et al. Choroidal vascular remodelling in central serous chorioretinopathy after indocyanine green guided photodynamic therapy with verteporfin: a novel treatment at the primary disease level. Br J Ophthalmol 2003;87:1453–1458.
14. Yannuzzi LA, Slakter JS, Gross NE, et al. Indocyanine green angiography guided photodynamic therapy for treatment of chronic central serous chorioretinopathy: a pilot study. Retina 2003;23:288–298.
15. Canakis C, Livir-Rallatos C, Panayiotis Z, et al. Ocular photodynamic therapy for serous macular detachment in the diffuse retinal pigment epitheliopathy variant of idiopathic central serous chorioretinopathy. Am J Ophthalmol 2003;136:750–752.
16. Taban M, Boyer DS, Thomas EL, et al. Chronic central serous chorioretinopathy: photodynamic therapy. Am J Ophthalmol 2004;137:1073–1080.
17. Chung SE, Kang JH, Kang SW. Chronic central serous chorioretinopathy: Photodynamic Therapy. J Korean Ophthalmol Soc 2007;48:279–284.
18. Schmidt-Erfurth U, Laqua H, Schlotzer-Schrehard U, et al. Histopathological changes following photodynamic therapy in human eyes. Arch Ophthalmol 2002;120:835–844.
19. Lai TY, Chan WM, Lam DS. Transient reduction in retinal function revealed by multifocal electroretinogram after photodynamic therapy. Am J Ophthalmol 2004;137:826–833.
20. Schlotzer-Schrehardt U, Viestenz A, Naumann GO, et al. Dose-related structural effects of photodynamic therapy on choroidal and retinal structures of human eyes. Graefes Arch Clin Exp Ophthalmol 2002;240:748–757.
21. Xu Tao;Li Yingxing,Wu Xing.Application of lower fluence rate for less microvasculature damage and greater cell-killing during photodynamic theray. Lasers Med Sci 2004;19:150–154.
22. Schmidt-Erfurth U, Michels S, Barbazetto I, et al. Photodynamic effects on choroidal neovascularization and physiological choroid. Invest Ophthalmol Vis Sci 2002;43:830–841.
23. Michels S, Schmidt-Erfurth U. Sequence of early vascular events after photodynamic therapy. Invest Ophthalmol Vis Sci 2003;44:2147–2154.
24. Henderson BW, Gollnick SO, Snyder JW, et al. Choice of oxygen-conserving treatment regimen determines the inflammatory response and outcome of photodynamic therapy of tumors. Cancer Res 2004;64:2120–2126.
25. Sacu S, Varga A, Michels S, et al. Reduced fluence versus standard photodynamic therapy in combination with intravitreal triamcinolone: short-term results of a randomised study. Br J Ophthalmol 2008;92:1347–1351.
26. Tzekov R, Lin T, Zhang KM, et al. Ocular changes after photodynamic therapy. Invest Ophthalmol Vis Sci 2006;47:377–385.
27. Michels S, Hansmann F, Geitzenauer W, Schmidt-Erfurth U. Influence of treatment parameters on selectivity of verteporfin therapy. Invest Ophthalmol Vis Sci 2006;47:371–376.
28. Azab M, Boyer DS, Bressler NM, et al. Verteporfin therapy of subfoveal minimally classic choroidal neovascularization in age-related macular degeneration: 2-year results of a randomized clinical tiral. Arch ophthalmol 2005;123:448–457.
29. Singh CN, Saperstein DA. Sapersein. Combination treatment with reduced-fluence photodynamic therapy and intravitreal injection of triamcinolone for subfoveal choroidal neovascularization in macular degeneration. Retina 2008;28:789–793.
30. Verteporfin in Photodynamic Therapy Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in Age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization-VIP report 2. Am J Ophthalmol 2001;131:541–560.
31. Verteporfin in Photodynamic Therapy Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin: one-year results of a randomized clinical trial-VIP report 1. Ophthalmology 2001;108:841–852.
32. Bressler NM. Treatment of Age-related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials-TAP report 1. Arch Ophthalmol 1999;117:1329–1345.
33. Treatment of Age-Related Macular Degeneration With Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials - TAP report 2. Arch Ophthalmol 2001;119:198–207.
34. Chan WM, Lai TY, Lai RY, et al. Half-dose verteporfin photodynamic therapy for acute central serous chorioretinopathy. One-year results of a randomized controlled trial. Ophthalmology 2008;115:1756–1765.
35. Lai TY, Chan WM, Lai RY, et al. Safety enhanced photodynamic therapy with half dose verteporfin for chronic central serous chorioretinopathy: a short term pilot study. Br J Ophthalmol 2006;90:869–874.
36. Kim JL, Kim HW, Yoon IH. Photodynamic therapy with verteporfin for short time for chronic central serous chorioretinopathy. J Korean Ophthalmol Soc 2008;49:1078–1086.